Zhong Yuan Bio-Tech Hldgs Stock (OTC: ZHYBF)

Latest news for Zhong Yuan Bio-Tech Hldgs (OTC:ZHYBF) Stock

Zhong Yuan Bio-Technology Holdings Ltd is engaged in the business of developing and marketing nervonic acid-based health supplements and sales of acer truncatum seedlings. The company has two reportable segments such as sales of health care supplements and technical supporting services. The company generates its revenue primarily from the sales of health care supplements.

ZHONG YUAN BIO-TECHNOLOGY by Zhong Yuan Bio-Technology Holdings Ltd

Zhong Yuan Bio-Technology Holdings Ltd

MicroAlgo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) shares are trading higher Thursday after the company announced the development of a hybrid <a href="https://www.benzinga.com/pressreleases/25/01/n42763951/microalgo-inc-develops-hybrid-classical-quantum-algorithms-to-optimize-multi-query-problems">classical-quantum algorithm.</a>
What To Know: The algorithm addresses Multi-Query Optimization (MQO) problems, which are classified as NP-hard and have applications in fields like database query optimization, machine learning and network routing. The innovation combines the stability of classical computing with the efficiency of quantum computing.
Key aspects of the algorithm include efficient qubit utilization with a reported 99% efficiency, the integration of classical error correction mechanisms to reduce computational error rates, scalability to handle problems of different sizes and compatibility with existing gate-based quantum computers.
MicroAlgo claims its algorithm can effectively handle smaller-scale MQO problems while improving qubit utilization and reducing computational error rates. Experimental evaluations reportedly confirm its performance under current quantum computing limitations.
MLGO Price Action: MicroAlgo shares were up 7.7% at $4.05 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga pro.</a>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="545" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02105044/Screenshot-2025-01-02-at-10.50.02-1024x545.png" alt="" class="wp-image-715496" style="width:421px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02105044/Screenshot-2025-01-02-at-10.50.02-1024x545.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02105044/Screenshot-2025-01-02-at-10.50.02-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02105044/Screenshot-2025-01-02-at-10.50.02-768x409.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02105044/Screenshot-2025-01-02-at-10.50.02.png 1499w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/01/42767647/chinese-stocks-drop-as-manufacturing-growth-slows-and-geopolitical-tensions-hit">Chinese Stocks Drop As Manufacturing Growth Slows And Geopolitical Tensions Hit</a></li>
</ul>
Photo by solarseven on Shutterstock.

News

Movers

MLGO

MicroAlgo Shares Are On The Rise today: What You Need To Know

Jefferies analyst David Katz maintains Choice Hotels Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHH#NYSE">CHH</a>) with a Hold and raises the price target from $150 to $152.

Price Target

Analyst Ratings

Jefferies Maintains Hold on Choice Hotels Intl, Raises Price Target to $152

Jefferies analyst David Katz maintains Wyndham Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WH#NYSE">WH</a>) with a Buy and raises the price target from $107 to $120.

Jefferies Maintains Buy on Wyndham Hotels & Resorts, Raises Price Target to $120

Rolex SA, the Swiss luxury watchmaker, has raised prices on several of its models following an upswing in gold prices in 2024, <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-01-02/rolex-kicks-off-2025-by-hiking-watch-prices-after-gold-soars?srnd=phx-industries&amp;sref=TBDibEcD" rel="noreferrer noopener">Bloomberg</a> reported.
According to the report, the price of the yellow gold Day-Date and yellow gold GMT-Master II has increased by almost 8% to 44,200 euros and 44,600 euros, respectively.
The price hikes follow gold&#8217;s remarkable 27% gain in 2024, reflecting its role as a safe-haven asset that remains prominent amid global economic uncertainties and geopolitical tensions.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/12/42666501/starbucks-faces-major-strike-on-christmas-eve-300-locations-affected-as-5000-workers-walk-out" rel="noreferrer noopener">Starbucks Faces Major Strike On Christmas Eve: 300+ Locations Affected As 5,000 Workers Walk Out</a>
While Rolex traditionally adjusts prices at the beginning of the year, this year&#8217;s changes surpass the 4% increases seen for some of its models in the beginning of 2024, Bloomberg noted.
According to a report, the gold prices are expected to continue their upward trajectory and reach $2,795 per troy ounce by the end of 2025, a <a target="_blank" href="https://www.benzinga.com/markets/commodities/25/01/42759408/gold-prices-to-climb-7-in-2025-amid-trumps-return-to-white-house-and-geopolitical-tensions-momentum-is-taking-back-over" rel="noreferrer noopener">7% increase from current levels</a>.
Central banks are likely to drive demand as they diversify reserves in the midst of geopolitical uncertainties.
Key drivers of the expected increase include central banks&#8217; diversification away from the U.S. dollar following sanctions on Russia, anticipated interest rate cuts by the U.S. Federal Reserve, and rising concerns about U.S. <a target="_blank" href="https://www.benzinga.com/24/12/42594797/trump-wants-to-get-rid-of-the-debt-ceiling-30-year-treasury-bonds-fall-to-2024-lows-stocks-cut-gains" rel="noreferrer noopener">government debt</a> under President-elect&nbsp;Donald Trump.
As per&nbsp;<a target="_blank" href="https://pro.benzinga.com/" rel="noreferrer noopener">Benzinga Pro</a>, gold ETFs have increased in the past year as of Tuesday, 31st Dec.&nbsp;SPDR&nbsp;Gold Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) was up by 26.85%,&nbsp;iShares Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAU#NYSE">IAU</a>) rose by 26.85%, and&nbsp;abrdn Physical Gold Shares ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGOL#NYSE">SGOL</a>) was up by 26.90%.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42729529/social-media-stocks-react-as-trump-targets-censorship-and-delays-tiktok-ban" target="_blank" rel="noreferrer noopener">Trump Administration to Challenge Social Media Censorship, Setting Stage for Conflict with EU Regulations</a></li>
</ul>
Photo by panlertb via Shutterstock

Commodities

Media

GLDM

OUNZ

SGOL

Gold Price Surge Pushes Rolex to Raise Prices for Iconic Watches

Looking into the current session, NVR Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVR#NYSE">NVR</a>) shares are trading at $8143.15, after a 0.44% decrease. Over the past month, the stock fell by 9.07%, but over the past year, it actually increased by 17.37%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1735835409_0.png" alt="Past Year Chart" />

<h3>Evaluating NVR P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 12.64 in the Household Durables industry, NVR Inc. has a higher P/E ratio of 16.74. Shareholders might be inclined to think that NVR Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1735835409_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

A Look Into NVR Inc's Price Over Earnings

American Tower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) has outperformed the market over the past 20 years by 3.71% on an annualized basis producing an average annual return of 12.05%. Currently, American Tower has a market capitalization of $85.06 billion. 
Buying $1000 In AMT: If an investor had bought $1000 of AMT stock 20 years ago, it would be worth $9,692.23 today based on a price of $182.02 for AMT at the time of writing.
<h3>American Tower's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735835408_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares are trading higher Thursday following <a href="https://www.benzinga.com/25/01/42761126/why-microstrategy-shares-are-trading-higher-by-over-5-here-are-20-stocks-moving-premarket">an increase in Bitcoin</a> (CRYPTO: BTC/USD)'s price to $96,578.38, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a>
What To Know: Despite gaining 342% year-to-date in 2024, MicroStrategy has experienced a 23% decline over the past month. The stock closed at $289.62 on Wednesday, trading below its eight, 20 and 50-day simple moving averages, signaling a bearish short-term trend. However, it remains above its 200-day moving average of $195.03, indicating long-term bullish potential.
Analysts have set a consensus price target of $449.50 for MicroStrategy, with a high of $690 from BTIG on Dec. 11, 2023, and a low of $140 from Jefferies on Nov. 10, 2022. Recent ratings from Bernstein, TD Cowen and Barclays in late 2024 suggest an average price target of $546.67, implying a potential upside of 77.91%.
The company's stock performance is directly tied to Bitcoin's fluctuations due to its heavy investment in the cryptocurrency. While Bitcoin&#8217;s rise has previously led to gains for MicroStrategy, it also exposes the company to volatility.
Galaxy Research projects that Bitcoin could exceed $150,000 in early 2025, with a potential peak of $185,000 by the year's end, driven by increased institutional and corporate adoption.
MSTR Price Action: MicroStrategy shares were up 4.33% at $302.67 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga pro.</a>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="521" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02102503/Screenshot-2025-01-02-at-10.24.35-1024x521.png" alt="" class="wp-image-715449" style="width:531px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02102503/Screenshot-2025-01-02-at-10.24.35-1024x521.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02102503/Screenshot-2025-01-02-at-10.24.35-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02102503/Screenshot-2025-01-02-at-10.24.35-768x391.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02102503/Screenshot-2025-01-02-at-10.24.35.png 1527w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/01/42766729/why-vs-media-holdings-vsme-stock-is-skyrocketing">Why VS Media Holdings (VSME) Stock Is Skyrocketing</a></li>
</ul>
Image via Shutterstock.

MSTR

MicroStrategy Shares Are Up Today: What's Going On?

Jefferies analyst David Katz maintains Hyatt Hotels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) with a Hold and raises the price target from $150 to $176.

Jefferies Maintains Hold on Hyatt Hotels, Raises Price Target to $176

Jefferies analyst David Katz maintains Hilton Worldwide Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) with a Hold and raises the price target from $237 to $277.

Jefferies Maintains Hold on Hilton Worldwide Holdings, Raises Price Target to $277

Rigetti Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) shares are trading higher by 13.3% to $17.28 Thursday morning, despite a lack of company-specific news for the session. Rigetti shares have gained some 445% over the past month amid marked strength in <a href="https://www.benzinga.com/markets/equities/24/12/42638753/quantum-computing-the-new-ai-a-look-at-the-rapidly-expanding-market-and-top-stocks-for-2025">quantum computing-related stocks</a>.
Additionally, the company&#8217;s December release of its 84-qubit Ankaa-3 quantum computer has also <a href="https://www.benzinga.com/news/mid-cap/24/12/42654955/why-are-rigetti-computing-shares-surging-on-monday">captured investor attention</a>.
What To Know: Ankaa-3 features superior two-qubit gate fidelities, achieving 99.0% for iSWAP gates and 99.5% for fSim gates, coupled with reduced error rates. The company says these improvements are critical for advancing quantum computing toward practical applications in cryptography, optimization and drug discovery. 
Rigetti Computing says the system also delivers fast gate speeds—72-nanosecond median times for iSWAP and 56 nanoseconds for fSim—ideal for complex data processing tasks like random circuit sampling.
The company says the machine is now accessible through Rigetti Quantum Cloud Services and will debut on platforms like Amazon Braket and Microsoft Azure in early 2025. 
Rigetti&#8217;s forward-looking plans include a modular 36-qubit system in mid-2025 and a 100+ qubit system by year-end, with further reductions in error rates.
CEO Dr. Subodh Kulkarni in December also highlighted Rigetti&#8217;s <a href="https://www.benzinga.com/pressreleases/24/12/g42646200/rigetti-computing-launches-84-qubit-ankaa-3-system-achieves-99-5-median-two-qubit-gate-fidelity-mi">$225 million cash position</a> and absence of debt, emphasizing confidence in delivering its roadmap.
Read Also: <a href="https://www.benzinga.com/25/01/42766117/tesla-stock-tumbles-on-q4-deliveries-whats-going-on">Tesla Stock Tumbles On Q4 Deliveries: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy RGTI Stock</h2>
By now you're likely curious about how to participate in the market for Rigetti Computing &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the the case of Rigetti Computing, which is trading at $15.58 as of publishing time, $100 would buy you 6.42 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, RGTI has a 52-week high of $19.35 and a 52-week low of $0.66.

RGTI

What's Going On With Rigetti Computing (RGTI) Stock?

Jefferies analyst David Katz maintains Marriott Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) with a Hold and raises the price target from $251 to $295.

Jefferies Maintains Hold on Marriott Intl, Raises Price Target to $295

<a href="https://www.theinformation.com/articles/predictions-2025-amazon-will-buy-lyft">https://www.theinformation.com/articles/predictions-2025-amazon-will-buy-lyft</a>
&nbsp;

AMZN

LYFT

Watching Lyft; Shares See A Pop To The Upside After The Information Posts 'Predictions 2025: Amazon Will Buy Lyft'

Jefferies analyst Chris Howerton maintains Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) with a Buy and lowers the price target from $11 to $8.

ARDX

Jefferies Maintains Buy on Ardelyx, Lowers Price Target to $8

Piper Sandler analyst David Amsellem maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Overweight and lowers the price target from $26 to $9.

SAGE

Piper Sandler Maintains Overweight on Sage Therapeutics, Lowers Price Target to $9

Jefferies analyst Peter Abramowitz maintains Sun Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>) with a Buy and lowers the price target from $145 to $142.

Jefferies Maintains Buy on Sun Communities, Lowers Price Target to $142

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy and maintains $77 price target.

Reiteration

CAPR

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $77 Price Target

Piper Sandler analyst Christopher Raymond downgrades Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) from Overweight to Neutral and lowers the price target from $315 to $138.

Downgrades

BIIB

Piper Sandler Downgrades Biogen to Neutral, Lowers Price Target to $138

Jefferies analyst Peter Abramowitz upgrades Equity Lifestyle Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELS#NYSE">ELS</a>) from Hold to Buy and raises the price target from $72 to $80.

Upgrades

Jefferies Upgrades Equity Lifestyle Props to Buy, Raises Price Target to $80

Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH).
Sotatercept is used, in combination with other medicines, to treat PAH in adults with moderate or marked physical activity limitations and improve exercise capacity.
The <a target="_blank" href="https://www.gov.uk/government/news/sotatercept-approved-to-treat-adult-patients-with-pulmonary-arterial-hypertension-pah" rel="noreferrer noopener">recommended</a> dosing schedule is one injection every three weeks via self-administration.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42638844/large-biopharma-lags-market-jp-morgans-2025-outlook-on-eli-lilly-merck-and-more" rel="noreferrer noopener">Big Biopharma Trails Behind The Market: JP Morgan&#8217;s 2025 Outlook on Eli Lilly, Merck, and More</a>
In March 2024, the FDA approved&nbsp;Winrevair (sotatercept-csrk), for injection, 45mg, 60mg for adults with PAH to increase exercise capacity, improve WHO functional class, and reduce the risk of&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37958211/mercks-11b-bet-pays-as-fda-approves-sotatercept-for-rare-lung-disease" rel="noreferrer noopener">clinical worsening events</a>.&nbsp;
A main study was conducted involving 323 patients with PAH. The study showed that sotatercept was more effective than placebo at improving the ability of adults with PAH to exercise. The main measure of effectiveness was the difference in the distance patients could walk in 6 minutes before and after treatment.
After 24 weeks of treatment, sotatercept given in addition to other PAH medicines, improved the distance patients could walk in 6 minutes by around 34 meters, compared with 1 meter in patients who received a placebo instead. The median (average) treatment difference between the sotatercept and placebo groups was 40.8 meters.
In November, Merck&nbsp;revealed topline results from the Phase 3 ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) III or IV at&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42169558/why-is-merck-stock-trading-higher-on-monday" rel="noreferrer noopener">high risk of mortality</a>.
ZENITH met its primary endpoint of time to first morbidity or mortality event (all-cause death, lung transplantation, or PAH worsening-related hospitalization of ≥ 24 hours).
Price Action: MRK stock is up 0.56% at $100.04 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42766874/equinor-powers-up-empire-wind-1-project-with-financing-package-details" target="_blank" rel="noreferrer noopener">Equinor Powers Up Empire Wind 1 Project With Financing Package: Details</a></li>
</ul>
Image via Merck

Biotech

Large Cap

Health Care

General

UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal

First Citizens BancShares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) has outperformed the market over the past 20 years by 6.48% on an annualized basis producing an average annual return of 14.82%. Currently, First Citizens BancShares has a market capitalization of $29.56 billion. 
Buying $100 In FCNCA: If an investor had bought $100 of FCNCA stock 20 years ago, it would be worth $1,554.59 today based on a price of $2113.02 for FCNCA at the time of writing.
<h3>First Citizens BancShares's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735834511_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Zhong Yuan Bio-Tech Hldgs

News

Latest news for Zhong Yuan Bio-Tech Hldgs (OTC:ZHYBF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga